Clinical trialNCT06057948RecruitingPhase 2Interventional

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment94High-risk NeuroblastomaMetastatic NeuroblastomaNeuroblastoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Brian Kushner, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Memorial Sloan Kettering at Basking Ridge (consent Only)
Basking Ridge, New Jersey, United States
Recruiting
Memorial Sloan Kettering Monmouth (consent Only)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering Bergen (consent Only)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Suffolk-Commack (consent Only)
Commack, New York, United States
Recruiting
Memorial Sloan Kettering Westchester (consent Only)
Harrison, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
Recruiting
Memorial Sloan Kettering Nassau (consent Only)
Uniondale, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

OPT-821

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Sept 2023
Primary completion: 21 Mar 2027
Completion: 21 Mar 2027
Last update posted: 28 Jul 2026
Registered enrollment: 94
Registry id: NCT06057948

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.